Roger Jelliffe

Dr. Roger Jelliffe


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ABAida Bustad
Aida Bustad
DTDimiter Terziivanov
Dimiter Terziivanov
RLRobert Leary
Robert Leary
RPRuediger Port
Ruediger Port
ASAlan Schumitzky
Alan Schumitzky
RJRoger Jelliffe
Roger Jelliffe

1 June 2015 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
RJRoger Jelliffe
Roger Jelliffe
ASAlan Schumitzky
Alan Schumitzky
DBDavid Bayard
David Bayard
XFXiaowei Fu
Xiaowei Fu
MNMichael Md Neely
Michael Md Neely
Background: Describing assay error as percent coefficient of variation (CV%) fails as measurements approach zero. Results are censored if below some arbitrarily chosen lower limit of quantification (LLOQ). CV% gives incorrect weighting to data obtained by therapeutic drug monitoring, with incorrect parameter values in the resulting pharmacokinetic models, and incorrect dosage regimens for patient care. Methods: CV% was compared with the reciprocal of the variance (1/var) of each assay measurement. This method has not been considered by the laboratory community. A simple description of assay standard deviation (SD) as a polynomial function of the assay measurement over its working range was developed, the reciprocal of the assay variance determined, and its results compared with CV%. Results: CV% does not provide correct weighting of measured serum concentrations as required for optimal therapeutic drug monitoring. It does not permit optimally individualized models of the behavior of a drug in a patient, resulting in incorrect dosage regimens. The assay error polynomial described here, using 1/var, provides correct weighting of such data, all the way down to and including zero. There is no need to censor low results, and no need to set any arbitrary LLOQ. Conclusions: Reciprocal of variance is the correct measure of assay precision and should replace CV%. The information is easily stored as an assay error polynomial. The laboratory can serve the medical community better. There is no longer any need for LLOQ, a significant improvement. Regulatory agencies should implement this more informed policy.

18 May 2011 in Journal of Theoretical Biology
Verified
Journal Article
Open access
SGSylvain Goutelle
Sylvain Goutelle
LBLaurent Bourguignon
Laurent Bourguignon
RJRoger Jelliffe
Roger Jelliffe
JCJohn E. Conte
John E. Conte
PMPascal Maire
Pascal Maire
There is a critical need for improved and shorter tuberculosis (TB) treatment. Current in vitro models of TB, while valuable, are poor predictors of the antibacterial effect of drugs in vivo. Mathematical models may be useful to overcome the limitations of traditional approaches in TB research. The objective of this study was to set up a prototype mathematical model of TB treatment by rifampin, based on pharmacokinetic, pharmacodynamic and disease submodels. The full mathematical model can simulate the time-course of tuberculous disease from the first day of infection to the last day of therapy. Therapeutic simulations were performed with the full model to study the antibacterial effect of various dosage regimens of rifampin in lungs. The model reproduced some qualitative and quantitative properties of the bactericidal activity of rifampin observed in clinical data. The kill curves simulated with the model showed a typical biphasic decline in the number of extracellular bacteria consistent with observations in TB patients. Simulations performed with more simple pharmacokinetic/pharmacodynamic models indicated a possible role of a protected intracellular bacterial compartment in such a biphasic decline. This modeling effort strongly suggests that current dosage regimens of RIF may be further optimized. In addition, it suggests a new hypothesis for bacterial persistence during TB treatment.

1 August 2012 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
RJRoger Jelliffe
Roger Jelliffe
Population pharmacokinetic and dynamic modeling is often employed to analyze data of steady-state trough serum digoxin concentrations in the course of what is frequently regarded as routine therapeutic drug monitoring (TDM). Such a monitoring protocol is extremely uninformative. It permits only the estimation of a single parameter of a 1-compartment model, such as clearance. The use of D-optimal design strategies permits much more information to be obtained, employing models having a really meaningful structure. Strategies and protocols for routine TDM policies greatly need to be improved, incorporating these principles of optimal design. Software for population pharmacokinetic modeling has been dominated by NONMEM. However, because NONMEM is a parametric method, it must assume a shape for the model parameter distributions. If the assumption is not correct, the model will be in error, and the most likely results given the raw data will not be obtained. In addition, the likelihood as computed by NONMEM is only approximate, not exact. This impairs statistical consistency and reduces statistical efficiency and the resulting precision of model parameter estimates. Other parametric methods are superior, as they provide exact likelihoods. However, they still suffer from the constraints of assuming the shape of the model parameter distributions. Nonparametric methods are more flexible. One need not make any assumptions about the shape of the parameter distributions. Nonparametric methods also provide exact likelihoods and are statistically consistent, efficient, and precise. They also permit maximally precise dosage regimens to be developed for patients using multiple model dosage design, something parametric modeling methods cannot do. Laboratory assay errors are better described by the reciprocal of the assay variance of each measurement rather than by coefficient of variation. This is easy to do and permits more precise models to be made. This also permits estimation of assay error separately from the other sources of uncertainty in the clinical environment. This is most useful scientifically. Digoxin has at least 2-compartment behavior. Its pharmacologic and clinical effects correlate not with serum digoxin concentrations but with those in the peripheral nonserum compartment. Some illustrative clinical examples are discussed. It seems that digitalis therapy, guided by TDM and our 2 compartment models based on that of Reuning et al, can convert at least some patients with atrial fibrillation and flutter to regular sinus rhythm. Investigators have often used steady-state trough concentrations only to make a 1-compartment model and have sought only to predict future steady-state trough concentrations. Much more than this can be done, and clinical care can be much improved. Further work along these lines is greatly to be desired.

10 November 2010 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
IBI. B. Bondareva
I. B. Bondareva
RJRoger Jelliffe
Roger Jelliffe
OAO. V. Andreeva
O. V. Andreeva
KBK. I. Bondareva
K. I. Bondareva
What is known and Objective: Many investigators agree that appropriate rational utilization of therapeutic drug monitoring (TDM) with Bayesian feedback dosage adjustment facilitates epilepsy treatment with carbamazepine (CBZ) and/or valproate (VPA) by increasing the seizure control and safety, as well as by reducing treatment costs. In previous works we have developed and used in clinical practice population pharmacokinetic (PK) models of different dosage forms for VPA and post‐induction CBZ behaviour, as well as for combined therapy with CBZ plus another ‘old’ antiepileptic drug (AED). An important step of external validation is to evaluate how well a procedure of Bayesian individualizing AED dosage regimens based on a proposed population PK model and sparse TDM data ‘works’, and how helpful it is in real practical clinical settings. The aim of this study was to evaluate the predictability of individualized dosage regimens for monotherapy with CBZ in the post‐induction period or with VPA, as well as for CBZ and VPA given as combination therapy based on TDM data of epileptic patients and the earlier developed population models. Methods: Four groups of TDM data were analysed using the USC*PACK software for PK/PD analysis: 556 predictions for adult epileptic patients on CBZ monotherapy, 662 predictions for VPA monotherapy, 402 predictions of CBZ serum levels and 430 predictions of VPA serum levels for adult epileptic patients on CBZ+VPA combination therapy. Statistical characteristics of the prediction errors (PE) and weighted PE were used to estimate bias and precision of predictions. Intraindividual and interoccasional variability of predictions were also estimated. Results and Discussion: This study demonstrated that in most cases of CBZ and VPA monotherapy and combination therapy, predictions of future AED concentrations based on the earlier developed population PK models, TDM data and patient‐specific maximum a posteriori probability Bayesian posterior parameter values provided clinically acceptable estimates. Statistical analysis of the residuals demonstrated that the distributions of residual and weighted residual were close to the normal distribution (Kolmogorov–Smirnov test, P > 0·05) and their mean values did not differ statistically significant from zero (no statistically significant bias, P > 0·05) for all groups of predictions. The observed decreased quality of predictions of VPA concentrations during VPA+CBZ combination therapy, especially when CBZ dosages were changed, might well be explained by their PK interactions. For all groups, in linear regression analysis, the observed trend of decreasing of the prediction quality over various future prediction time horizons was considered statistically significant (P < 0·05). Prediction of serum levels further in future was less precise than those closer to the present for a 1·5‐ to 3·5‐year observation period. No bias in predictions was associated with the time horizons. What is new and Conclusion: Our validation results suggest good predictive performance of the population models developed earlier, and quite acceptable predictions of future AED serum levels for individualized dosage regimens of CBZ and VPA therapy in real clinical settings.

1 June 2014 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
RJRoger Jelliffe
Roger Jelliffe
MMMark Milman
Mark Milman
ASAlan Schumitzky
Alan Schumitzky
DBDavid Bayard
David Bayard
MGMichael Van Guilder
Michael Van Guilder
A population pharmacokinetic/pharmacodynamic model of digoxin in adult subjects was originally developed by Reuning et al in 1973. They clearly described the 2-compartment behavior of digoxin, the lack of correlation of effect with serum concentrations, and the close correlation of the observed inotropic effect of digoxin with the calculated amount of drug present in the peripheral nonserum compartment. Their model seemed most attractive for clinical use. However, to make it more applicable for maximally precise dosage, its model parameter values (means and SD's) were converted into discrete model parameter distributions using a computer program developed especially for this purpose using the method of maximum entropy. In this way, the parameter distributions became discrete rather than continuous, suitable for use in developing maximally precise digoxin dosage regimens, individualized to an adult patient's age, gender, body weight, and renal function, to achieve desired specific target goals either in the central (serum) compartment or in the peripheral (effect) compartment using the method of multiple model dosage design. Some illustrative clinical applications of this model are presented and discussed. This model with a peripheral compartment reflecting clinical effect has contributed significantly to an improved understanding of the clinical behavior of digoxin in patients than is possible with models having only a single compartment, and to the improved management of digoxin therapy for more than 20 years.